Daiichi Sankyo New R&D Head Puts Emphasis On Faster Decision-making
This article was originally published in PharmAsia News
Daiichi Sankyo has four large Phase III milestones in the next two years, followed by prioritization for early stage programs
You may also be interested in...
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.